The purpose of this proposal is to study the role of kallikrein- binding protein (KBP) in hypertension. Previous studies suggest that the tissue kallikrein-kinin system may be involved in blood pressure regulation. To date, no physiological regulators of this serine proteinase have been identified. With the support of this current grant, the applicants were the first to purify, characterize and clone KBP (designated as kallistatin), a novel serine proteinase inhibitor and putative regulator of the tissue kallikrein-kinin system. They have expressed KBP in heterologous cell expression systems and in transgenic mice. Through genetic analysis, they have found linkage between the KBP gene locus and salt-induced hypertension in spontaneously hypertensive rats. The present goal is to continue to analyze kallistatin's physiological function by the following specific aims. 1)Transgenic mice over-expressing KBP will be developed and these mice will be cross bred to other transgenic mice expressing kallikrein (already available in this laboratory). Phenotypic effects of KBP expression, such as changes in growth, development and blood pressure, will be monitored. The effect of KBP expression on kallikrein-induced hypotension and inflammation will be analyzed in mice carrying both kallikrein and KBP transgene. 2)The kallistatin gene will be inactivated by homologous recombination in mouse embryonic stem cells and its physiological function in these kallistatin-deficient mice will be evaluated. 3)The regulatory elements which control the expression of the KBP gene and the genetic basis of KBP's function in blood pressure regulation linked to the hypertensive phenotype will be analyzed by splicing its 5'- promoter region to a reporter gene and identifying the cis-acting elements and trans-acting factors by deletion analysis, gel retardation and footprinting assays. 4)Potential linkage between the human kallistatin gene and hypertension will be explored by examining affected sibling pairs and family pedigrees. The proposed studies employ multi- disciplinary approaches with state-of-the-art technologies. Understanding the role of kallistatin in the development of hypertension should provide important insights for improving the detection and treatment of cardiovascular diseases and stroke.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL044083-06
Application #
2221294
Study Section
Cardiovascular and Renal Study Section (CVB)
Project Start
1990-02-01
Project End
1999-01-31
Budget Start
1995-02-01
Budget End
1996-01-31
Support Year
6
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Biochemistry
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Chao, Julie; Bledsoe, Grant; Chao, Lee (2016) Protective Role of Kallistatin in Vascular and Organ Injury. Hypertension 68:533-41
Chao, Julie; Bledsoe, Grant; Chao, Lee (2014) Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res 69:37-57
Li, Pengfei; Bledsoe, Grant; Yang, Zhi-Rong et al. (2014) Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology 142:216-26
Zhang, Jingmei; Yang, Zhirong; Li, Pengfei et al. (2013) Kallistatin antagonizes Wnt/*-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem 379:295-301
Zhu, Haidong; Chao, Julie; Kotak, Ishita et al. (2013) Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. Metabolism 62:642-6
Liu, Yuying; Bledsoe, Grant; Hagiwara, Makato et al. (2012) Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol 303:F1230-8
Shen, Bo; Chao, Lee; Chao, Julie (2010) Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol 298:H1048-54
Chao, Julie; Shen, Bo; Gao, Lin et al. (2010) Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem 391:345-55
Yin, Hang; Gao, Lin; Shen, Bo et al. (2010) Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension 56:260-7
Shen, Bo; Gao, Lin; Hsu, Yi-Te et al. (2010) Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol 299:H1419-27

Showing the most recent 10 out of 68 publications